Management of multiple myeloma: The changing landscape
- 30 November 2007
- journal article
- review article
- Published by Elsevier BV in Blood Reviews
- Vol. 21 (6), 301-314
- https://doi.org/10.1016/j.blre.2007.07.001
Abstract
No abstract availableKeywords
This publication has 84 references indexed in Scilit:
- A Comparison of Allografting with Autografting for Newly Diagnosed MyelomaNew England Journal of Medicine, 2007
- Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 studyBlood, 2006
- Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialThe Lancet, 2006
- Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2006
- Weekly Cyclophosphamide and Alternate-Day Prednisone: An Effective, Convenient, and Well-Tolerated Oral Treatment for Relapsed Multiple Myeloma After Autologous Stem Cell TransplantationMayo Clinic Proceedings, 2005
- Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myelomaBlood, 2005
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myelomaBritish Journal of Haematology, 2005
- Clinical Course of Patients With Relapsed Multiple MyelomaMayo Clinic Proceedings, 2004
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003